Merck & Co. Inc. [NYSE: MRK] stock went on a downward path that fall over -0.06% on Friday, amounting to a one-week price increase of more than 1.80%. The company report on August 19, 2020 that Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer.
KEYTRUDA Is First Anti-PD-1 Therapy in Combination With Chemotherapy to Show Superior Survival Benefit as First-Line Treatment for Patients With Esophageal Cancer Regardless of Histology .
Results of Phase 3 KEYNOTE-590 Trial to be Submitted to Global Regulatory Authorities .
Over the last 12 months, MRK stock dropped by -2.01%. The one-year Merck & Co. Inc. stock forecast points to a potential upside of 10.55. The average equity rating for MRK stock is currently 1.90, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $215.06 billion, with 2.53 billion shares outstanding and 2.53 billion shares in the current float. Compared to the average trading volume of 9.15M shares, MRK stock reached a trading volume of 6411482 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Merck & Co. Inc. [MRK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRK shares is $95.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRK stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Merck & Co. Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 03, 2020. The new note on the price target was released on June 12, 2020, representing the official price target for Merck & Co. Inc. stock. Previously, the target price had yet another raise to $93, while Barclays analysts kept a Overweight rating on MRK stock.
The Average True Range (ATR) for Merck & Co. Inc. is set at 1.45, with the Price to Sales ratio for MRK stock in the period of the last 12 months amounting to 4.56. The Price to Book ratio for the last quarter was 7.77, with the Price to Cash per share for the same quarter was set at 4.39. Price to Free Cash Flow for MRK in the course of the last twelve months was 62.94 with Quick ratio for the last quarter at 1.10.
MRK Stock Performance Analysis:
Merck & Co. Inc. [MRK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.80. With this latest performance, MRK shares gained by 8.86% in over the last four-week period, additionally plugging by 4.49% over the last 6 months – not to mention a drop of -2.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRK stock in for the last two-week period is set at 72.35, with the RSI for the last a single of trading hit 76.55, and the three-weeks RSI is set at 64.95 for Merck & Co. Inc. [MRK]. The present Moving Average for the last 50 days of trading for this stock 79.33, while it was recorded at 84.87 for the last single week of trading, and 81.89 for the last 200 days.
Insight into Merck & Co. Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Merck & Co. Inc. [MRK] shares currently have an operating margin of +28.62 and a Gross Margin at +70.25. Merck & Co. Inc.’s Net Margin is presently recorded at +21.13.
Return on Total Capital for MRK is now 25.31, given the latest momentum, and Return on Invested Capital for the company is 20.52. Return on Equity for this stock inclined to 37.42, with Return on Assets sitting at 11.79. When it comes to the capital structure of this company, Merck & Co. Inc. [MRK] has a Total Debt to Total Equity ratio set at 105.57. Additionally, MRK Total Debt to Total Capital is recorded at 51.35, with Total Debt to Total Assets ending up at 32.41. Long-Term Debt to Equity for the company is recorded at 90.72, with the Long-Term Debt to Total Capital now at 44.13.
Reflecting on the efficiency of the workforce at the company, Merck & Co. Inc. [MRK] managed to generate an average of $138,634 per employee. Receivables Turnover for the company is 6.73 with a Total Asset Turnover recorded at a value of 0.56.Merck & Co. Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.
MRK Stock EPS
With the latest financial reports released by the company, Merck & Co. Inc. posted 1.51/share EPS, while the average EPS was predicted by analysts to be reported at 1.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Merck & Co. Inc. go to 6.25%.
Merck & Co. Inc. [MRK] Insider Position Details
There are presently around $161,669 million, or 76.60% of MRK stock, in the hands of institutional investors. The top three institutional holders of MRK stocks are: VANGUARD GROUP INC with ownership of 212,784,687, which is approximately -1.94% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 197,558,293 shares of the stock with an approximate value of $16.79 billion in MRK stocks shares; and STATE STREET CORP, currently with $10.09 billion in MRK stock with ownership of nearly 1.234% of the company’s market capitalization.
Positions in Merck & Co. Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,292 institutional holders increased their position in Merck & Co. Inc. [NYSE:MRK] by around 96,941,035 shares. Additionally, 1,022 investors decreased positions by around 112,350,625 shares, while 294 investors held positions by with 1,693,139,234 shares. The mentioned changes placed institutional holdings at 1,902,430,894 shares, according to the latest SEC report filing. MRK stock had 131 new institutional investments in for a total of 8,701,888 shares, while 97 institutional investors sold positions of 4,037,841 shares during the same period.